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Methicillin-resistant Staphylococcus aureus (MRSA) causes nosocomial, community and 
livestock-associated infections. MRSA strains harbor diverse mobile genetic elements 
(MGEs), including plasmids, pathogenicity islands, transposons, integrons and prophages, 
which comprise 15-25% of the genome encoding resistance and virulence genes. We 
investigated resistance and virulence genes in the plasmids of 27 MRSA clinical isolates from 
the private healthcare sector in Durban, South Africa. 
 
MRSA was confirmed by mecA gene identification on plasmids extracted using a commercial 
plasmid extraction kit. The isolates were subjected to antimicrobial susceptibility testing and 
molecular characterization of 4 common resistance encoding genes and four frequently 
encountered virulence factors: blaZ, aac (2’)-aph (6’’), ermC, and tetK, and, hla, hld, eta and 
LukS/F-PV by PCR using plasmid DNA as the template. The genetic relatedness between the 
isolates was determined by pulsed field gel electrophoresis (PFGE). 
 
All MRSA isolates contained plasmids, and were resistant to ampillicin, while 85.2% were 
resistant to ciprofloxacin, 74.1% to gentamicin, 70.4% to rifampicin, 66.7% to tetracycline, 
63.0% to erythromycin, and 11.1% to clindamycin. They were also all susceptible to 
daptomycin, linezolid, vancomycin, tigecycline and fusidic acid.  Multidrug resistance (MDR) 
was found in 74.1% (20/27) of the MRSA isolates. The frequency of the resistance genes blaZ, 
aac (2’)-aph (6’’) and ermC were 100%, 92.6%and 48.2% respectively, while tetK was not 
found in any of the MRSA isolates. The prevalence of virulence genes hla and hld were 96.3% 
and 92.6% respectively, however, eta and LuKS/F-PV were not detected. PFGE analysis 
revealed 10 pulsotypes, designated A–J, which correlated with the resistance profile and 
mechanism of the isolates in each group. 85.2% (23/27) of the isolates clustered into six major 
PFGE types, giving an indication of similar circulating MRSA clones. Type F was the major 




10 were found to contain pulsotypes C and H, whiles identical pulsotypes F and G were 
identified in nine of the 15 centers, indicating the possibility of inter health centers spread of 
MRSA in the province. 
The complexity and diversity of molecular resistance and virulence profiles poses a challenge 
for MRSA infection management.  A comprehensive understanding of the molecular 










INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
Staphylococcus aureus has persisted as one of the fundamental human pathogens, causing a 
variety of infections in hospital and community settings.  S. aureus possess a remarkable 
number of resistance and virulence factors, and a unique capacity to adapt and survive under 
different host conditions, making it successful as a pathogen (1). Although Staphylococci were 
naturally susceptible to penicillin G, the distribution of penicillinase-encoding plasmids in the 
1950s caused the rapid emergence of resistance. Penicillinase production has become a 
species-related trait of most staphylococcal strains (2),  the main challenge being depicted by 
methicillin-resistance (MR), mediated by the acquisition of the penicillin-binding protein 2A 
(PBP2A), which the mecA gene encodes. This PBP2A enables the staphylococci to escape 
inhibition by methicillin and other penicillinase-stable beta-lactams by taking over the 
functions of the other PBPs (3). Methicillin-resistant Staphylococcus aureus (MRSA) strains 
also harbor other mobile genetic elements (MGEs), including plasmids, pathogenicity islands, 
transposons, integrons and prophages, which comprise 15-25% of the genome. MGEs carry 
the majority of the genes, through which strains of staphylococcal vary from each other, such 
as resistance and virulence genes (4). MGEs play a significant role in bacterial survival and 
adaptability, as they encode many antibiotic resistance determinants and virulence factors, 
hence understanding their composition will broaden our knowledge on their genetic 
determinants  (5). 
 
Glycopeptide vancomycin is currently used as a primary treatment for MRSA, as the number 
of therapeutic options has decreased over time. Predictably, the increase in vancomycin usage 
has caused the emergence of resistance, with the resulting reduction in its efficacy against 
MRSA. Reports of infection by strains resistance to the newest drugs available (daptomycin, 
vancomycin, teicoplanin), and their rapid dissemination, are of major concern as they introduce 




MRSA acquisition, and completely characterizing the molecular epidemiology and clinical 
properties of these strains are vital for effectively managing infections (6). 
Epidemiological and pathogenicity studies on MRSA in most African countries are limited, 
with South Africa being no exception (7). The Pan-European Antimicrobial Resistance Using 
Local Surveillance (PEARLS) study showed resistance to methicillin to be 33.3% for South 
African strains isolated during the 2001–2002 national survey (8).  Prevalence studies of 
MRSA in specific South African settings have been conducted, with the varying rates being 
influenced by the geographical location, study population and clinical practices (9, 10). MRSA 
infection increases health care cost and treatment complications, and is associated with higher 
mortality rates (11, 12). All efforts should be geared towards preventing the spread of resistant 
and virulent MRSA worldwide clones. 
 
1.2 Staphylococcus aureus 
Staphylococcus aureus is a Gram-positive, facultative anaerobic, coagulase- and catalase-
positive, coccus-shaped bacterium in the family Micrococcaceae. S. aureus is an opportunistic 
pathogen that can be found in human as well as animals, such as cats, dogs, pigs and horses. A 
typical 24-h Staphylococcal colony is large, β-haemolytic and cream-yellow pigmented on 
blood agar (13, 14). It is protected against many toxic molecules by an outer layer, the cell wall 
consisting of teichoic acids and peptidoglycan, which are connected to the cytoplasmic 
membrane (15). In addition, the staphylococcal cell wall is connected to many supporting 
surface proteins. The majority of all clinical S. aureus strains are protected by a polysaccharide 
capsule, with 11 unique putative capsule serotypes (16).The genome of the S. aureus is 
composed of a single circular chromosome with transposons, insertion sequences, genomic 
islands and plasmids. Prophages and pathogenicity islands are also considered to play vital 
roles in the virulence and evolution of S. aureus (22). Complete Staphylococcal genomes have 
been obtained through various genome sequencing methods (23). 
 
Although S. aureus has been regarded as an extracellular pathogen, various studies have shown 
that it can survive in different eukaryotic cells, including osteoblasts, fibroblasts, epithelial 




human monocyte-derived macrophages (17), which contributes to the recurrent and/or 
persistent nature of certain infections.  S. aureus mutants, known as ‘small colony variants’ 
(SCVs), are slow-growing colonies that are 10-fold smaller than normal bacteria, and have 
characteristics such as reduced haemolytic activity, low coagulase activity, decreased pigment 
formation, decreased toxin production and resistance to aminoglycosides (18). SCVs show 
similar metabolic characteristics in the central metabolism regardless of the fundamental 
auxotrophism, and have the ability to persist intracellularly as well as to cause persistent and 
recurrent infections (19). 
  
1.2.1 Infections  
Staphylococcus aureus causes many infections, ranging from soft skin to lethal conditions. The 
most common infection by S. aureus is superficial skin inflammation, which presents as a boil 
or furuncle. Common subcutaneous and skin infections caused by S. aureus include impetigo, 
folliculitis, carbuncles, mastitis and cellulitis. S. aureus can also cause chronic skin infections 
within human populations with some major disorders such as. More severe S. aureus infections 
include myocarditis, arthritis, pericarditis, osteomyelitis, endocarditis, scalded skin syndrome, 
pneumonia, and bacteraemia (20, 21).  S. aureus bacteraemia often emanates from various 
infection sources, such as deep tissue abscesses, osteomyelitis, pneumonia and septic 
pulmonary emboli (22, 23). Foreign bodies, such as endoprostheses and intravenous catheters, 
can also originate S. aureus bacteraemia (20). Several infections caused by Staphylococcal are 
toxin-mediated, including toxic shock syndrome (TSS), impetigo, food poisoning and 
necrotising pneumonia. TSS is caused by a potent super-antigen called toxic shock syndrome 
toxin 1, he symptoms including rash, hypotension, high fever and the involvement of multiple 
organ systems (24). Self-limiting staphylococcal food poisoning is caused by ingested 
enterotoxins via contaminated food, with the symptoms including headache, vomiting and 
diarrhea (25).  
 
S. aureus bacteraemia in the era of pre-antibiotics was mostly fatal, with reported mortality 
rates observed over a seven year period in the early 1940s in Boston City Hospital being 82% 




a main cause of hospital-associated infections, with a large proportion of these being caused 
by MRSA (27). The mortality rate associated with  MRSA infections differs noticeably 
between studies in various locations (28). In a large cohort study in Europe, the duration and 
mortality of bloodstream infections attributable to S. aureus were evaluated. The outcomes 
demonstrated the clinical significance of S. aureus invasive bacteria, and highlighted the extra 
burden imposed by resistance for 30 day mortality (29). In a Canadian study (2000-2006), S. 
aureus bacteraemia mortality rate was 4–6 deaths per 100 00 persons (30). In Africa, few 
studies targeting only S. aureus infections have been reported, with the percentage of S. aureus 
bacteraemia  differing considerably between countries, with as high as 52% in Egypt, 45% in 
Algeria, 44% in Botswana and 19% in Morocco (31, 32). The prevalence rate of S. aureus 
bacteraemia within South Africa varies, based on the population studied and geographical 
setting (33-35).  
 
1.2.2 Carriage 
S. aureus colonises multiple sites in the body, with the anterior nares of the nose being the 
most consistent carriage site in humans. Other typical sites for S. aureus colonisation include 
the skin, pharynx, gastrointestinal tract, axillae, perineum and vagina (36). Recent studies 
suggests that approximately 25–35% of healthy humans carry S. aureus on the mucous or skin 
membranes (36). Predictions from careful estimations based on the US and Dutch prevalence 
data indicate that approximately 53 million individuals carry MRSA (37). In a longitudinal 
carrier studies on S. aureus, three carrier patterns have been assigned: non-carriers, intermittent 
carriers and persistent carriers, with various criteria for assigning an individual to specific 
carriage patterns. Most studies use a cross-sectional study design with a single nasal culture, 
with  Van Belkum and co-workers in their 2009 studies predicting persistent and non-persistent 
as the only two types of S. aureus nasal carriers (38). Persistent nasal carriage is known as the 
main risk factor for causing infections in different locations. It is also the major risk factor in 
patients with intravascular devices and human immunodeficiency virus (HIV) infection, and 
those undergoing haemodialysis and surgery. The prevalence of nasal colonisation with S. 




of 38.4% (39). In the USA, similar studies conducted in 2008 reported a decrease in S. aureus 
nasal colonisation from 32.4% to 26.8% (40).  
 
1.2.3 Genome Composition 
The S. aureus genome has a comparatively low G+C content and a size of approximately 2.5 
- 2.9 Megabase pairs (Mbp), with up to 3 additional-chromosomal plasmids. It also harbors 
between 2600 and 2750 genes (41). The complete structure of the S. aureus genome is made 
up of a core and accessory genomes, which are well conserved (4) with only the accessory 
genomes being explored in this study.  
 
The accessory genome of  S. aureus was acquired through lateral gene transfer from other 
bacterial species, and accounts for approximately 25% of any S. aureus genome (5). The 
accessory genome mainly consists of mobile genetic elements that transfer horizontally 
between strains and make S. aureus a notorious hospital pathogen. These mobile genetic 
elements that will be explored further include plasmids, transposons, chromosome cassettes, 
pathogenecity and genomic islands (4). Many of these genetic determinants carry genes with 
antibiotic resistance, as well as virulence molecules and functions. Mobile genetic elements 
identification and characterization provides insight into infection, pathogenesis and the 
evolution of S. aureus. The horizontal transfer and distribution of these determinants can 
therefore have significant clinical consequences (42).  
 
a. Staphylococcal Cassette Chromosome (SCC): SCC is a fundamental mobile genetic 
element that serves as the medium for gene transmission within the staphylococcal species.  It 
belongs to the SCC family and specialises as a methicillin resistance carrier. It is a genomic 
island fixed at the 3‘end of open reading frame X (orf X), and is found near the origin of 
replication of S. aureus. The structure of SCCmec consists of the ccr and the mec gene 
complexes. The ccr gene complex encodes the recombinases responsible for its mobility and 
contains two site specific recombines genes, ccrA and ccrB.  The mec gene complex encodes 





b. Pathogenecity Islands of S. aureus: S. aureus pathogenicity islands  are a group of 15-27 
kb genetic elements that usually carry one or more super-antigen genes, encoding toxic shock 
syndrome toxin 1 (TSST-1) and/or enterotoxins. Pathogenecity Islands of S. aureus are firmly 
integrated at distinct chromosomal sites, but can be moved following infection by certain 
staphylococcal bacteriophages or by inducting endogenous prophages (44). S. aureus 
pathogenicity islands are believed to be formed by integrating extra chromosomal DNAs 
(plasmids) or by incorporating bacteriophages carrying toxin genes, which may transform a 
non-toxic into toxic strain (45). 
 
c. Plasmids in S. aureus: Plasmids are significant genetic vehicles that carry antibiotic 
resistance and virulence genes. Various forms of plasmids encoding for specific genes has been 
reported in staphylococci. For example, the plasmid pUB110 is found embedded into the type 
II SCCmec of some strains of S. aureus and encodes resistance to tobramycin, kanamycin, 
aminoglycosides and bleomycin.  The plasmid pI258 encodes resistance to heavy metals and 
penicillins, while the pT181 plasmid also encodes tetracycline resistance (46, 47). 
 
d. Transposons in S. aureus: Transposons (Tn) are minute transferable fragments of DNA 
that are located in the chromosome of S. aureus. They inactivate or modify certain cellular 
functions by transposing beside or into the genes involved in the function (48). Macrolide-
lincosamide-streptogramin B (MLSB) and spectinomycin resistance is located on the Tn 554. 
Transposons carrying genes responsible for resistance to gentamycin, tobramycin and 
kanamycin are the Tn552 containing the blaZ pencillinase gene and Tn4001 containing aacA-
aphD gene (42, 49). 
 
e. Genomic islands (GIs): This is a term given to non-SCC genomic and non-phage islands 
(20-30 kb in size) found exclusively in S. aureus (50). These GIs frequently encode virulence 
determinants inserted at a specific locus in the chromosome. In S.aureus each genomic island 
is found in various allelic forms with diverse sets of resistance or virulence genes. As each 




carries provides information on the overall properties of the isolate, i.e. its pathogenic potential 
and the antibiotic susceptibility patterns (51).   
 
1.2.4 Virulence factors and pathogenesis 
The ability of bacteria to cause an infection in humans is largely due to an evasion of the host’s 
immune system, with S. aureus playing a role in disease pathogenesis by expressing a number 
of distinct virulence factors. The complex interaction between the virulence factors of the S. 
aureus infecting strain and host defence mechanisms determines the severity and form of the 
infection. Each virulence factor may have various functions in pathogenesis, and multiple 
virulence factors may execute an identical function. Pathogenesis in Staphylococci is 
multifactorial, involving three factors that are directly or indirectly injurious: cell surface 
components, cell-surface-bound proteins, and secreted proteins. Secreted proteins, including 
tissue-degrading enzymes (lipases, proteases), cytotoxins [e.g. α, β, γ, δ–haemolysin, Panton-
Valentine leukocidin (PVL)], and super-antigens [e.g. enterotoxins A-D, exfoliatins A-B, toxic 
shock syndrome toxin-1 (TSST-1)], allow bacteria to penetrate and destroy the local structural 
and cellular elements of host organs and tissues (52-54).  
 
Two genes are found on the prophage encode the PVL toxin (55), which is harmful to 
neutrophils causing tissue necrosis. It is associated with severe necrotising pneumonia as well 
as soft and skin tissue infections (56). The release of PVL has also been associated with 
community-acquired methicillin-resistant S. aureus (CA-MRSA) strains (57). Microbial 
surface components recognising adhesive matrix molecules (MSCRAMMs) are among the 
numerous surface proteins found in S. aureus, and include collagen-binding, fibrinogen-
binding and fibronectin-binding protein, as well as adhesins (58). MSCRAMMs play an active 
role in mediating their attachment to bacterial cells, host tissues, the inert and extracellular 
surfaces.  They also aid in initiating prosthetic-device, endovascular, joint and bone infections 
(17, 53).  
 
The Staphylococcal protein A (Spa) is the best known surface protein of S. aureus, being first 




related immunoglobulin G (IgG)-binding domains, a polymorphic region X and C- terminal 
cell wall attachment sequence (60, 61), with the X region containing a highly polymorphic 
sequence of 24 bp repeats (62). Spa blocks the normal function IgG by binding to its Fc region, 
which causes an inhibition of the phagocytosis that are disguising the bacterium from the innate 
immune system by preventing opsonisation-dependent activation of the complement cascade 
(63). Due to the highly variable X-region, spa typing is a universally used genotyping method 
for comparing S. aureus isolates (64).  Each cell surface component has a different role in the 
pathogenesis of S. aureus, with the mucoid capsule inhibiting phagocytosis by covering C3b 
complement factor bound to the cell wall (65). However, the function of the capsules involved 
in the pathogenesis of S. aureus is controversial.  
 
A complex regulatory network controls the staphylococcal virulence factors encoding genes. 
The surface protein genes are released shortly after the pre-exponential growth phase during 
the establishment of an infection. This enables adherence to the host tissues and protects the 
bacteria from host defenses, such as complement-mediated killing and opsonisation-
phagocytosis. Other genes encoding secreted enzymes and cytotoxins are released during the 
post-exponential growth phase to aid in spreading the bacteria, acquiring nutrients and killing  
phagocytes (52). The accessory gene regulation (agr) locus is the main global regulatory 
system of S. aureus (66). Additionally, three other two-component signalling modules are 
known to be involved in staphylococcal virulence genes regulation. Environmental factors, 
such as temperature, CO2, O2 and pH levels, also affect the overall regulatory system by 
helping the bacterium to recognise and respond appropriately to its local environments (52, 
66).  
 
1.3 Molecular detection 
Many molecular based techniques are available to identify MRSA, the ‘gold standard’ being 
mecA gene detection. Multiplex PCR assays that concurrently target mecA gene and that are 
specific for some S. aureus, including spa, coa, femA, nuc or all staphylococci, e.g. 16S rDNA 
conserved genus sequences, have been developed (67-69). Genomic DNA extracts from broth 




methods can produce false positive results if the culture contains a mixture of methicillin-
susceptible and methicillin resistant coagulase negative staphylococci. Recently, MRSA was 
detected within one to six hours directly from screening swabs using commercially available 
real-time PCR assays.  
 
1.4 Typing methods 
Phenotypic or genotypic characters are generated by typing strains within a species to predict 
the routes and sources of spread of the micro-organisms. Typing contributes to understanding 
the study bacterial genetic population structures and infectious diseases pathogenesis. Data 
from typing help to define the relatedness of isolates implicated in an outbreak and elucidates 
its chain of transmission (70). Microbial typing systems should be evaluated and validated with 
respect to different performance criteria, including typeability, discriminatory power, 
reproducibility, stability, convenience criteria and epidemiological concordance (71). It can be 
used at various levels: (i) globally, through international surveillance networks; (ii) 
nationally/regionally, in reference laboratories, or (iii) locally at hospital or health-care 
institutions. The choice of methods and quality assessment depends solely on the level at which 
typing is performed, with phenotypic characters showing limited performance, reliability and 
specificity. In genotyping, comparisons based on the sequence polymorphism or genomic 
DNA fragments are the most preferred techniques. Typing systems can be grouped as 
definitive (‘library’ system) or comparative, which are often the same ‘typing run’, and enable 
comparisons of isolates in the same laboratory. The latter can be enough for an outbreak 
investigation, but it poses difficulties when comparing results with future or past data samples. 
In contrast, a definitive typing system has the advantage to compare typing data produced in 
various laboratories, by different investigators at a range of time intervals, and generates 
standardised and reproducible data. The most frequently used molecular typing methods are 








1.4.1 Pulsed-field gel electrophoresis (PFGE) 
This typing methodology employs a restriction enzyme (SmaI in the case of S. aureus) for 
digesting chromosomal DNA and agarose gel electrophoresis using an alternating voltage 
gradient. A software package was used to analyze the banding patterns, this being one of the 
most popular methods, which helps to detect genetic variation between staphylococcal strains 
(73). However, PFGE is less reproducible and does not involve a selective amplification step, 
hence it has a limited use for long-term epidemiology surveillance or for studying the 
phylogenetic and evolutionary relationship among Staphylococcus aureus strains (74).  
 
1.4.2 Multi locus sequence typing (MLST) 
MLST is a genotypic technique for bacterial strain characterization that uses DNA sequencing 
to reveal allelic variants in various conserved genes (75). MLST offers the advantages of high 
degrees of typeability, unambiguous identification and reproducibility based on the nucleotide 
sequences of 450-500bp internal fragments of seven housekeeping genes. Data obtained by 
MLST also permits an investigation of the population structure, and the development and 
testing of evolutionary hypotheses (76). The main advantage of this technique is its ability for 
sequence data to be compared and contrasted between different laboratories through the MLST 
website, making it suitable for local and global epidemiology of S. aureus and other bacterial 
pathogens (77). 
1.4.3 Spa typing 
Spa typing is based on variations of the polymorphic X region of staphylococcal protein A 
(spa) locus (78). The highly polymorphic X region is suited directly upstream of the region 
encoding the C-terminal cell wall attachment sequence, and is characterized by a variable 
number of 24 bp repeats (70, 73). Its discriminatory power falls between that of MLST and 
PFGE. Spa typing involves sequencing only one locus, which makes the technique simple 
compared to MLST. Another advantage over MLST is its ability to investigate both hospital 
outbreaks of MRSA and molecular evolution (79). It also allows laboratories to use diverse 
sequencing platforms and specialised software (Bionumerics software) to interpret the 





1.4.4 SCCmec Typing 
This is a technique used to investigate the structure of SCCmec. A multiplex PCR assay for 
identifying mecA and various loci on SCCmec was developed to determine the specific 
SCCmec types, which are based on the allotype of ccr genes and the mec gene complex (80-
82).  
 
1.4.5 Whole Genome Sequencing (WGS) 
WGS is a technology that is advancing our understanding of MRSA evolution, especially 
during epidemics, with various WGS studies of MRSA isolates from outbreaks having been 
published (83-85). This method includes sequencing DNA fragments and aligning them to a 
complete and well-annotated reference genome sequence. It can be used to detect lineage, as 
well as single nucleotide polymorphisms (SNPs) variation in the core genome (86). A few 
studies have also investigated additional DNA found in the test isolates that are not found in 
the reference genome, indicating that it is also a reliable method for identifying mobile genetic 
elements (MGE) variation. Bioinformatic data analysis is currently complex, and user friendly 
algorithms to identify spa, MLST type and the presence of key virulence and resistance genes 
are being developed. There are good prospects that this technology could be widely 
incorporated into infection control outbreak investigation in real time (87).  
 
1.5 Justification for the study 
Although research has been done on MRSA in South Africa, few have been done on its genetic 
determinants, with little information being available on the content and resistance of MRSA 
plasmids in the private health sector in South Africa. There is therefore a need to delineate 
antibiotic resistance patterns, compare their plasmids profiles and establish the possible genetic 
relatedness of MRSA in the private sector, as this will increase the evidence base to optimize 






The study aims to establish the clonality and characterize the plasmid-encoded antibiotic 
resistance and virulence profile of 27 clinical MRSA isolates collected from a private 
pathology laboratory in Durban, South Africa. 
 
1.7 Objectives 
1. To verify the identity of the clinical isolates using cefoxitin disc diffusion (CDD) test and 
polymerase chain reaction (PCR) - based mecA gene detection technique. 
2. To determine the minimum inhibitory concentration (MIC’s) to the following antibiotics: 
ampicillin, ciprofloxacin, gentamicin, erythromycin, clindamycin, tetracycline, linezolid, 
daptomycin, fusidic acid, tigecycline, rifampicin and vancomycin.   
3. To establish the presence of resistance genes (blaZ, tetK, ermC, aac-aph) and specific 
virulence genes (PVL genes (lukS/F-PV, eta, hla, hld) on plasmids DNA using PCR. 
4. To study the clonal relatedness of the isolates using pulse field gel electrophoresis (PFGE). 
5. To establish possible correlations between particular plasmid types, antimicrobial 
susceptibility and the clonal lineages of isolates for their genetic relatedness using PFGE. 
 
1.8 Outline  
This study is presented in three chapters, the first outlining the rationale for the research, as 
well as the Aim and Objectives.  As this dissertation is presented in manuscript format, it 
contains the following two chapters:  
Chapter 2 outlines the characterization of plasmid-mediated resistance and virulence genes in 
clinical MRSA isolates in private sector in KZN province and their genetic relatedness. This 
section has been submitted to the International Journal of Infectious Diseases and formatted 
according to the journal’s standards.  
Chapter 3, the final chapter presents the conclusions, limitations and recommendations arising 
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      Abstract 
Objectives: There is limited information on the plasmid content of MRSA strains from South 
Africa. We investigated resistance and virulence genes in the plasmids of 27 MRSA clinical 
isolates from the private healthcare sector in Durban, South Africa and their genetic 
relatedness. 
Methods: MRSA was confirmed by mecA gene identification in plasmids extracted using a 
commercial plasmid extraction kit. The isolates were subjected to antimicrobial susceptibility 
testing and molecular characterization of four common resistance encoding genes and four 
frequently encountered virulence factors: blaZ, aac (2’)-aph (6’’), ermC, tetK, hla, hld, eta and 
LukS/F-PV respectively by PCR using plasmid DNA as the template.  The genetic relatedness 
between the isolates was determined by pulsed field gel electrophoresis (PFGE). 
Results: All MRSA isolates contained plasmids. The isolates were 100% resistant to 
ampillicin, 85.2% were resistant to ciprofloxacin, 74.1% to gentamicin, 70.4% to rifampicin, 
66.7% to tetracycline, 63.0% to erythromycin, and 11.1% to clindamycin. They were all 
susceptible to daptomycin, linezolid, vancomycin, tigecycline and fusidic acid.  Multidrug 
resistance (MDR) was found in 74.1% (20/27) of the MRSA isolates. The frequency of the 
resistance genes blaZ, aac (2’)-aph (6’’) and ermC were 100%, 92.6% and 48.2% respectively, 
but tetK was not found in any of the MRSA isolates. The prevalence of virulence genes hla 
and hld were 96.3% and 92.6% respectively, however, eta and LuKS/F-PV were not detected. 
PFGE analysis revealed 10 pulsotypes, designated A–J, which correlated with the resistance 
profile and mechanism of the isolates in each group. Of note, 85.2% (23/27) of the isolates 
clustered into six major PFGE types giving an indication of similar circulating MRSA clones. 
Type F was the major pulsotype (29. 6%) and was found in eight of the 27 MRSA isolates. 
Hospital centers 1 and 10 contained pulsotypes C and H, whiles identical pulsotypes F and G 
were spread across nine of the 15 facilities, intimating the possibility of inter-health center 
spread of MRSA in the province. 
Conclusions: The complexity and diversity of the molecular resistance and virulence profiles 
poses a challenge for managing MRSA infections. A comprehensive understanding of the 
molecular epidemiology is essential to inform treatment and contain dissemination. 





The World Health Organization (WHO) and the African Health Observatory (AHO) have 
increasingly recognized the significance of  tracking  antibiotic resistance, specifically the 
resistance mechanisms and their dissemination, to optimize managing infections and provide 
the basis for evaluating the effectiveness of infection control programmes.1, 2 One of the 
fundamental human pathogens is Staphylococcus aureus, an adaptive bacterium that causes 
superficial, deep and fatal diseases. The ability of S. aureus strains to cause infection depends 
on various resistance and virulence factors that contribute to its colonization and disease 
development in the host.3  S. aureus has gradually developed resistance towards all the main 
classes of antibiotics to which it was once susceptible.4 
 
MRSA strains, whose definitive characteristic is the mecA carrier element called 
staphylococcal cassette chromosome mec (SCCmec), confer resistance to methicillin,  causing 
nosocomial, community and livestock-associated infections that have resulted in major public 
health, economic and social problems worldwide 5, 6 These strains also harbor mobile genetic 
elements (MGEs), including plasmids, pathogenicity islands, transposons, integrons and 
prophages, which comprise 15-25% of the genome.  MGEs carry the majority of the genes, 
through which strains of staphylococcal may be differentiated from each other.7 As MGEs play 
a significant role in bacterial survival and adaptability because they encode many resistance 
and virulence genes, understanding their composition will broaden our knowledge on the 
genetic determinants of antibiotic resistance.8  
 
The most significant MGEs are plasmids, which aid antibiotic resistance genes transmission 
and carriage. Plasmids of staphylococcal vary in size from 1 to over 200 kb, and are classified 
according to their mutual incompatibility, size and replication mechanism.9 S. aureus possess 
a wide variety of plasmid-borne genes, with many of the currently sequenced plasmids 
containing open reading frames (ORFs) that have not been described.10 
 
Although research has been conducted on MRSA in Africa, the recently available information 




data on their resistance in the South Africa private sector being lacking.  A study of this nature 
is a necessity, as understanding antibiotic resistance patterns, comparing the plasmids profiles, 
and assessing the possible relatedness of MRSA isolates is useful for epidemiological studies 
and evaluating the effectiveness of infection control. The aim of this study was to ascertain the 
clonality, and characterize the plasmid-encoded antibiotic resistance and virulence profile of 
27 clinical MRSA isolates obtained from a private laboratory in Durban, KwaZulu-Natal 
Province, South Africa. 
 
2. Materials and Methods 
 
2.1. MRSA isolates and mecA gene confirmation 
A total of 27 consecutive non-repetitive MRSA isolates were obtained from a pathology 
laboratory based in Durban, South Africa, over a three months period, from June to August, 
2015, that caters for the private healthcare sector. The isolates were identified using Vitek 2 
(bioMerieux, Durham, NC, USA) and confirmed by matrix assisted laser desorption ionization 
time of flight mass spectrometry (MALDI-TOF/MS).  The cefoxitin disc diffusion (CDD) test 
was used to identify putative MRSA11, 12, which were confirmed by PCR detection of the mecA 
gene.13 S. aureus ATCC 29213 (susceptible to methicillin) and S. aureus ATCC 43300 
(resistant to methicillin) were used as controls. 
 
2.2. Antimicrobial agents and MIC determinations 
    The minimum inhibitory concentration (MIC) was determined for 12 antibiotics by the 
broth microdilution method.14 They included ampicillin (β-lactams), ciprofloxacin 
(fluoroquinolones), erythromycin (marcolides), gentamicin (aminoglycosides), tetracycline 
(tetracyclines), rifampicin (ansamycins), clindamycin (lincosamides), linezolid, daptomycin 
(lipopeptides), fusidic acid, vancomycin (glycopeptides) and tigecycline (glycylcyclines). The 
Clinical and Laboratory Standards Institute (CLSI) Guideline14  was used for interpreting the 
results, and Staphylococcus aureus ATCC 29213 was used as the control. Isolates resistant to 





2.3. Molecular characterization of plasmid-borne resistance and virulence determinants by 
PCR 
     A plasmid DNA extraction kit (GeneJET Plasmid Miniprep kit, Thermoscentific) was used 
to purify the plasmid DNA from all 27 MRSA strains, according to the manufacturer’s 
instructions. The presence of resistance genes conferring resistance to ampicillin-penicillin 
(blaZ), aminoglycoside (aac (6’)–aph (2’’)), macrolide-lincosamide-streptogramins B [MLSB] 
(ermC) and tetracycline (tetK) were determined using PCR.15 The virulence determinants 
encoding the bio-component Panton-Valentine leukocidin (LukS/F-PV gene), exfoliative toxin 
(eta), alpha and delta hemolysin genes (hla and hld) were also ascertained by PCR.16 All 
specific primers and programs for detecting antibiotic resistance and virulence determinants 
can be found in Table 1.15,16. Positive and negative controls were included in all PCR assays. 
 
2.4. Pulsed-field gel electrophoresis (PFGE)  
     PFGE was used to determine the genetic relationship between the isolates17. The 
Bionumerics software version 6.6 (Applied Maths NV, Belgium) using the Dice coefficient, 
and represented by unweighted pair group method with arithmetic mean (UPGMA) with 
optimization settings and position tolerance set at 0.5% and 1% respectively was used to 
analyze the electrophoretic patterns. Clusters were defined using the criterion of a difference 
of ≤ 6 bands, as described by Tenover et al 18, and a similarity cut-off of ≥70.0%.  Salmonella 
serotype Braenderup strain H9812 was used as the quality control strain for normalization 




3.1. Patient demographics and clinical sources of infection 
    All 27 laboratory-confirmed mecA-positive MRSA isolates constituted the study sample. 
Of the available isolates, 22 had complete data, such as hospital center, specimen source, ward 
type, date of sample collection, gender and age (Table 3). Demographic data reflected 10 males 
(37.0%) and 13 females (48.2%), while four patients had no record for gender. The median age 




isolates. Five (18.5%) were classified as paediatric isolates, and 18 isolates (66.7%) as adult 
isolates. Nineteen isolates (70. 4%) were collected from in-patients, three (11.1%) from 
outpatients, with five (18.5%) being unknown. The intensive care unit (ICU) yielded nine 
(33.3%) isolates, that largest number of all ward types.  
 
3.2. Antimicrobial resistance pattern  
    The resistance patterns of the 27 MRSA isolates and the MIC distributions of the tested 
antimicrobial agents are shown in Tables 2 and 3. Ampicillin showed no activity against 
MRSA isolates, while 85.2% (23/27) were resistant to ciprofloxacin, 74.1% (20/27) to 
gentamicin, 70.4% (19/27) to rifampicin, 66.7% (18/27) to tetracycline, 63.0% (17/27) to 
erythromycin, and 11.1% (3/27) to clindamycin.  All isolates were susceptible to daptomycin, 
linezolid, fusidic acid, tigecycline and vancomycin. Multidrug resistance (MDR) was 
determined in 74.1% (20/27) of the MRSA isolates. 
 
3.3. Prevalence of the genetic determinants of resistance and virulence 
     The prevalence of four resistance genes and four virulence factors on extracted plasmids 
of the 27 clinical MRSA isolates are shown in Table 3. The penicillin resistance gene, blaZ, 
was amplified from all 27 MRSA isolates. The aac (6’)–aph (2’’) gene for aminoglycoside 
resistance and the ermC gene for macrolide-lincosamide-streptogramins [MLSB] resistance 
were amplified from 25 (92.6%) and 13 (48.2%) isolates respectively. The tetracycline 
resistance gene (tetK) was not detected in any of the 27 MRSA isolates. The most prevalent 
virulence gene was alpha hemolysin hla, which was identified in 26 (96.3%) isolates, followed 
by delta hemolysin hlddentified in 25 (92.6%) of isolates. However, Panton-Valentine 
leukocidin lukS/F-PV and exfoliative toxin eta were not detected. 
 
3.4. Genetic relationship by PFGE 
    The PFGE profiles and the dendrogram of the MRSA isolates are shown in Figure 3. PFGE 
analysis grouped the 27 isolates into 10 pulsotypes designated A-J, displaying 70.0% 
similarity, and correlating with their resistance profile and the genetic determinants tested in 




F (8/27 strains; 29.6%), G (5/27; 18.5%), C, I (3/27; 11.1%) and A, H (2/27; 7.4 %). Pulse 
types B, D, E and J were each represented by single isolates. PFGE types F and G were 
subdivided into five and three subtypes respectively.  Hospital centers 1 and 10 were found to 
contain pulsotypes C and H, while identical pulsotypes F and G were spread across nine 
centers, intimating the possibility of inter-health centers spread of MRSA in the province. 
 
4. Discussion 
Antibiotic resistance is a global health problem and MRSA remains a prominent multi-drug 
resistant bacterial species, which presents a challenge to clinicians, as the introduction of new 
classes of antibiotics is usually followed by the emergence of resistant pathogenic forms. 
Antibiotic resistance surveillance and delineating resistance and virulence genes in MRSA 
isolates is essential to understand their genetic basis and inform their management. 
 
The majority of the MRSA isolates in this study were resistant to ciprofloxacin, gentamicin, 
rifampicin, tetracycline and erythromycin. Notwithstanding the small sample size of 27 
isolates, resistance rates in this study were in some cases lower than those seen in another KZN 
study on 61 confirmed MRSA isolates by Shittu et al19, particularly for gentamicin (74.1% vs. 
96.7%), rifampicin (70.4% vs. 73.8%), tetracycline (66.7% vs. 90.2%) and erythromycin 
(63.0% v. 82.0%). Resistance to clindamycin of 11.1% was also much lower in this 
investigation than the rates of 82%19, 62.5%20, 34%21 reported in other studies conducted on 
MRSA isolates in KZN and South Africa. Only the ciprofloxacin resistance rate in our study 
was notably higher (85.2% v. 18%19), with its resistance on MRSA isolates in South Africa 
having been reported to 69.7% and 88.7% in the private sector.20 Multidrug resistance rate was 
lower (74.1% vs. 87%) than those reported by Shittu et al19 but similar to a study by Heysell 
et al22 in KZN with a rate of 79% on 19 clinical MRSA.    
 
All MRSA isolates were susceptible to daptomycin, vancomycin, linezolid, fusidic acid and 
tigecycline, while only ampillicin showed 100% resistance. The susceptibility patterns of the 
isolates in this study were comparable to studies conducted on MRSA in South Africa19, 20, 23 




and tigecycline. The full susceptibility of MRSA to these antibiotics observed in this study 
confirms their use as treatment options for infections in South Africa.  
 
There was a relationship between resistance to methicillin and to other antibiotics, as noted in 
other investigations25-27.  The presence of mecA is an absolute requirement for S. aureus to 
express methicillin resistance28. The structural component of mecA encodes the penicillin-
binding protein 2a (PBP2a) that establishes resistance to methicillin, other semisynthetic 
penicillinase-resistant beta-lactams that are frequently co-carried with genes conferring 
resistance to aminoglycosides, macrolide-lincosamide-streptogramin B [MLSB] and 
spectinomycin29. All the isolated plasmids of the 27 MRSA isolates contained the mecA and 
blaZ resistance genes, indicating the correlation between MICs and the presence of genes 
encoding resistance against beta-lactams. The gentamicin resistance gene aac (6’)–aph (2’’) 
was identified in 92.6% of the isolates, which varied from the phenotypic resistance profile of 
74.1%, indicating that gene carriage does not necessarily translate into the resistance 
phenotype. This result was similar to the studies conducted in Turkey by Duran et al30, where 
17 gentamicin-susceptible isolates were found to be positive, in terms of one or more 
gentamicin resistance genes mostly aac (6’)–aph (2’’). The ermC gene responsible for 
macrolide-lincosamide-streptogramins B [MLSB] resistance was amplified in 48.2% (13/27) 
of the MRSA isolates, while it was not found in those that were susceptible to both 
erythromycin and clindamycin. The 23.5% (4/17) with phenotypic resistance to MLSB that did 
not contain the ermC gene indicates the occurrence of other resistance mechanism, ermA, ermB 
and msrA, which was not investigated in this study but have been previously reported.31 This 
confirms that the incidence of MLSB phenotypes and genotypes vary according to country, 
patterns of infections and drug use.31, 32 Although there was high tetracycline resistance, the 
tetK gene was not detected, indicating that it this may be due to different mechanisms and not 
mediated by active drug efflux, as tetK resistance has so far not been reported in clinical MRSA 
studies in South Africa. 
 
The prevalence of virulence factors in all isolated plasmids showed a similar trend, with the 




92.6% (25/27) respectively. Comparatively, this was similar to other studies conducted from 
Iran16, Uganda33 and United States34, with either hla being more frequent than the hld genes, 
or both showing 100% co-dominance. The prevalence rate of eta in our study was 0%, which 
was similar to studies conducted in Japan35 and China36, where no eta was detected in 197 and 
62  clinical MRSA isolates respectively. However, the prevalence of eta differed among 
studies, which could be associated with a variety of geographical and health conditions37. 
LuKS/F-PV was not detected in any of the 27 clinical MRSA isolates, which was comparable 
to a study conducted in South Africa on 320 clinical MRSA isolates with only one positive 
LuKS/F-PV gene being detected38. Generally, the resistance and virulence profiles showed a 
similar trend in all the plasmids, indicating closely related MRSA isolates. 
 
PFGE, which is the gold standard for strain typing, was able to predict the genetic relatedness 
of the MRSA isolates.17 The analysis revealed 10 pulsotypes, designated A–J, which correlated 
with the resistance profile and mechanism of the isolates in each group (Fig. 2). Isolates of 
group G were all resistant to the five antibiotics, and were clustered in 3 subtypes. These 
isolates also clustered at a similarity of 0.75 when analyzed by smaI PFGE. Pulsotype C 
showed susceptibility to both tetracycline and rifampicin. Of note was that 85.2% (23/27) of 
the isolates clustered into six major PFGE types, indicating similar circulating MRSA clones 
in health centers in the province, as predicted by Shittu et al39 and Moodley et al38 in their 
study in KZN and South Africa respectively. Although the sample size was too small to show 
a definite correlation, the assertion of similar circulating clones in the province was supported 
by our study, as the PFGE analysis revealed some form of association between pulsotypes and 
the centers of sample collection. Centers 1 and 10 were found to contain pulsotypes C and H, 
while identical pulsotypes F and G were spread across nine of the 15 centers, intimating the 
possibility of similar clones of MRSA within the health care centers in the province. However, 
the study could not relate the pulsotypes to specific reported clones, as spa, SCCmec and multi 
locus sequence typing (MLST) are needed in tandem, with the PFGE for to predict the 





To the best of our knowledge this is the first study of clinical MRSA isolates in the private 
sector in KZN Province characterizing the plasmid-mediated resistance and virulence genes. 
The study provides a private sector perspective of antibotic suscepbility patterns, and strongly 
affirms reports of interhealth centres spread of identical and closely related clones of MRSA 
in Durban, South Africa, highlighting the need for implementing efficeint and effective 
infection control programs.    
 
Acknowledgement 
We express our gratitude to Professor Olarniran Ademola and Mr. Collins Odjadjare of the 
School of Life Sciences, University of Kwa-Zulu Natal (UKZN), Durban, South Africa, for 
granting us access to Bionumerics software version 6.6 (Applied Maths NV, Belgium) to 
analyse PFGE. We thank the South African National Research Foundation and the College of 
Health Sciences, UKZN, for supporting and funding this project. The funders had no role in 




Permission to carry out this study was granted by the Biomedical Research Ethics Committee 
(BREC) (REF/No: BE394/15) of the University of KwaZulu-Natal (UKZN).  
 
Conflict of interest 
 Professor SY Essack is a member of the Global Respiratory Infection Partnership sponsored 







Figure 1. Patterns of agarose gel electrophoresis showing PCR products for isolated MRSA plasmid genes. 
Lanes M: DNA molecular size maker (1-Kb ladder; Thermo Fisher Scientific Inc, Massachusetts, USA) 












Figure 2: PFGE Smal genotypic types generated from 27 clinical MRSA isolates from private sector in KZN. Pretested 
Salmonella serotype Braenderup strain H9812 was used as the quality control strain. The R and S indicate resistance 
or susceptibility for ciprofloxacin, gentamicin, erythromycin, tetracycline and rifampicin respectively. The alphabets 
A –J shows the main pulsotype and subtype of each isolate. The numbers 1 – 15 indicates codes of the hospital centers 











































































































































































































        Table 1 
        PCR primers and cycling parameters for genes presented in this study 
Gene Primer/sequence                                                                  PCR conditions PCR size (bp)     Reference 
mecA F-AACAGGTGAATTATTAGCACTTGTAAG 
R-ATTGCTGTTAATATTTTTTGAGTTGAA 
30 s 94 °C, 30 s 55 °C, 1 min 72 °C       174            15 
blaZ F-ACTTCAACACCTGCTGCTTT 
R-TGACCACTTTTATCAGCAAC 








30 s 94 °C, 30 s 55 °C, 1 min 72 °C 
 
30 s 94 °C, 30 s 55 °C, 1 min 72 °C 
 
      190  
 
      227  
          15 
 
          15 
tetK F-TCG ATA GGA ACA GCA GTA 
R-CAG CAG ATC CTA CTC CTT 
30 s 94 °C, 30 s 55 °C, 1 min 72 °C       169            15 
hla F-CTGATTACTATCCAAGAAATTCGATTG 
R-CTTTCCAGCCTACTTTTTTATCAGT 
30 s 95 °C, 45 s 58 °C, 1 min 72 °C       209            16 
hld F-AAGAATTTTTATCTTAATTAAGGAAGGAGTG 
R-TTAGTGAATTTGTTCACTGTGTCGA 
30 s 95 °C, 45 s 58 °C, 1 min 72 °C       111            16 
eta F-GCAGGTGTTGATTTAGCATT 
R-AGATGTCCCTATTTTTGCTG 
30 s 95 °C, 45 s 54 °C, 1 min 72 °C        93            16 
LukS/F-PV F-ATCATTAGGTAAAATGTCTGGACATGATCCA 
R-GCATCAAGTGTATTGGATAGCAAAAGC 












Table 2  
         Minimum inhibitory concentration (MIC) distributions of antimicrobial agents for 27 MRSA isolates    
Antibiotic  
Resistance pattern, n (%)                 
 
   Distribution of MIC (mg/ ml) 
 R  S     <0.25       0.5          1        2       4              8       16      32       64      128       256       >512 
Ampicillin 27 (100)  0         0 0   0 0 0 0 0 0 0 1 1 25 
Ciprofloxacin 23 (85.2)  4 (14.8)         0 2   2 0 4 1 1 0 2 5 8 2 
Gentamicin 20 (74.1)  7 (25.9)         2 3   1 0 1 0 2 4 7 7 0 0 
Erythromycin 16 (59.3)  11 (40.7)         0 8   2 1 0 2 6 4 4 0 0 0 
Rifampicin 19 (70.4)  8 (29. 6)         7 1   0 0 0 0 0 0 1 5 8 5 
Tetracycline 18 (66.7)  9 (33.3)                   6 1   1 2 0 0 1 1 8 5 2 0 
Clindamycin 3   (11.1)  24 (88.9)         24 0   1 1 0 0 0 0 0 0 0 1 
Daptomycin 0  27 (100)         7 16   4 0 0 0 0 0 0 0 0 0 
Vancomycin 0  27 (100)         1 10  16 0 0 0 0 0 0 0 0 0 
Linezolid 0  27 (100)         0 0   4 23 0 0 0 0 0 0 0 0 
Fusidic acid 0  27 (100)         26 1   0 0 0 0 0 0 0 0 0 0 
Tigecycline 0  27 (100)         27 0   0 0 0 0 0 0 0 0 0 0 

















Clinical data, minimum inhibitory concentrations (MIC), and results of PCR for 27 MRSA isolates 
Isolate 
No. 


























































B11970 1 Blood Neo ICU F  NB  >512 0.5   32 8 ≤0.25 2 ≤0.25 1 1 2 ≤ 0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
P10781 15 Nasal OPD M 86 >512 256   64 32  512 256 ≤0.25 0.5 1 2 ≤0.25 ≤0.25  +     +     +      +       -   +       +     -    - 
P10747 2 CVP ICU F 66 >512 4 >64 64  512 128 ≤0.25 0.5 0.5 1 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
S37938 -  - - - - >512 256   16 32  256 64    2 0.5 1 2 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
S18155 3 ETT  ICU F 76 >512 256   64 64  256 128 ≤0.25 0.25 0.5 2 ≤0.25 ≤0.25  +  +  -   +    -   +    -  -    - 
B13178 5 Blood LW F 26 >512 256 >64 64  512 128 ≤0.25 0.5 1 2 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
440260 -  - - - - >512 >512 >64 64  256 128 ≤0.25 0.5 1 2 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
S18970 -  - - - - >512 256   64 32  512 64 ≤0.25 0.5 0.5 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
P11520 6 Pus  OPD M 62   512 >512  0.25 0.5 ≤0.25 ≤0.25 ≤0.25 0.5 1 2 ≤0.25 ≤0.25  +  +  -   -    -   +    +  -    - 
T5683 7 Nasal  OPD F 43 >512  8  0.5 0.5  256 32 ≤0.25 0.5 1 1 ≤0.25 ≤0.25  +  +  -   -    -   +    +  -    - 
B15227 1 Blood Neo ICU F NB >512  4  64 8 ≤0.25 ≤0.25 ≤0.25 1 1 1 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
P13563 -     - - M 49 >512 128 >64 0.5  128 16 ≤0.25 0.5 1 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
S22589 4 Sputum ICU M 49 >512 128 >64 0.5  128 64 ≤0.25 1 1 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
B15612 8 Blood ICU M 46 >512 128 >64 16  512 256 ≤0.25 1 1 2 ≤0.25 ≤0.25  +  +  -   +    -   +    -  -    - 
B15810 5 Pus  Surgical M 41 >512 256  32 16  128 64 ≤0.25 0.5 1 2 0.5 ≤0.25  +  +  +   +    -   +    +  -    - 
B15583 1 Blood ICU F 37 >512 16 >64 2  64 2 ≤0.25 0.5 1 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
S24463 10 ETT  ICU F 59   512  1  32 1 ≤0.25 ≤0.25   1 0.5 0.5 2 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
P15045 1 Wound  Surgical F 47 >512 64  64 16  256 64 ≤0.25 0.25 0.25 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
P15028 10 Eye  Nursery F NB    512 4  16 0.5  0.5 ≤0.25 ≤0.25 0.25 1 2 ≤0.25 ≤0.25  +  +  -   +    -   -    +  -    - 
P14890 11 Wound  ICU F 41   512 256  64 0.5  256 128 ≤0.25 0.5 1 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
P15558 1  CVP  Medical F 94   512 >512 0.12 1  256 ≤0.25 >512 0.5 0.5 1 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
P15469 12 Humerus General F 68   128  64  1 0.5 ≤0.25 0.5 ≤0.25 0.25 0.5 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
P15490 13 Bone  General M 63 >512 128   32 16  128 64 ≤0.25 0.25 0.5 2 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
P15742 6 cheek  Trauma M 29   256  0.5  0.5 16 ≤0.25 64 ≤0.25 0.25 0.5 2 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
P15825 14 Buttock  Paediatri M 5   512  1  0.5 0.5 ≤0.25 0.25 ≤0.25 0.25 1 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
P15793 2 Head Surgical M 10   512 256  64 32  256 32 ≤0.25 0.5 0.5 2 ≤0.25 ≤0.25  +  +  +   +    -   +    +  -    - 
T8060 -     - - - -   512  4  4 16  128 64 ≤0.25 0.5 0.5 2 ≤0.25 ≤0.25  +  +  -   +    -   +    +  -    - 
 
a. ETT, Endotracheal tube; CVP, Central venous cathete; ICU, Intensive/High care unit; LW, Labour ward: OPD, outpatient department, NB, Newborn (day 0), -, No information. 
b AP,  ampicillin; CP,  ciprofloxacin; GT,  gentamicin; ET,  erythromycin; RF,  rifampicin; TT, tetracycline; CM,  clindamycin; DP,  daptomycin; VM, vancomycin; LZ, linezolid; FA, fusidic acid; TG, tigecycline. 
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This study describes the antibiotic resistance pattern, characterizes plasmid-mediated 
resistance and, virulence genes and assesses the genetic relatedness of 27 clinical MRSA 
isolates from the private sector in KZN, South Africa. 
 
3.1 Conclusions 
The following conclusions were drawn from the study with respect to the study objectives:  
 All MRSA isolates contained the plasmid-mediated mecA gene.  
 The isolates were all (100%) resistant to ampillicin, 85.2% were resistant to 
ciprofloxacin, 74.1% to gentamicin, 70.4% to rifampicin, 66.7% to tetracycline, 63.0% 
to erythromycin, and 11.1% to clindamycin. 
 All MRSA isolates showed no resistance to daptomycin, linezolid, vancomycin, 
tigecycline and fusidic acid.   
 Multidrug resistance (MDR) defined as resistant to β-lactams along with at least three 
classes of antibiotics was found in 74.1% (20/27) of the MRSA isolates.  
 The frequency of the resistance genes blaZ, aac (2’)-aph (6’’) and ermC were 100%, 
92.6% and 48.2% respectively but tetK was not found in any of the MRSA isolates.  
 The prevalence of virulence genes hla and hld were 96.3% and 92.6% respectively, 
however eta and LuKS/F-PV were not detected.  
 PFGE analysis revealed 10 pulsotypes; designated A–J with 70.0% similarity which 
correlated with the resistance profile isolates in each group.  
 Type F was the major pulsotype (29. 6%). It was found in 8 of the 27 MRSA isolates. 
subdivided into 5 subtypes  
 Of note, 85.2% (23/27) of the isolates clustered into 6 major PFGE types giving an 
indication of similar circulating MRSA clones in the KZN province.  
 The hospital centers 1 and 10 were found to contain similar pulsotypes C and H, whiles 
identical pulsotypes of F and G were spread across 9 out 15 different centers intimating 





3.2 Limitations  
The following limitations are acknowledged for this study:  
 The short collection period of isolates yielded a small sample size which may have 
under- and/or over-estimated results. 
 The study sample for molecular profiling was limited to isolates from only one private 
laboratory in eThekwini Municipality hence the results cannot be extrapolated to KZN 
or to South African private health sector in general. 




That the following recommendations are made as a result of the findings from this study: 
 Further molecular studies should be conducted to investigate the mechanism of 
tetracycline resistance, including the role of efflux proteins (TetA, TetB, TetC, TetL), 
ribosomal protection (TetO, TetM) and modification proteins (Tet37, TetX). 
 Additional mechanisms of macrolide-lincosamide resistance, including the role of 
efflux pumps mediated by mrsA, the acquisition of ribosomal methylase enzyme (ermA, 
ermB) and drug modification (lnuA, lnuB) should be investigated. 
 The mechanisms of rifampicin and fluroquinolone resistance need to be studied in 
similar isolates. 
 Additional virulence factors, such as enterotoxins (sea-see, seg-seo, and seq), gamma 
hemolysins (hlg), toxic shock syndrome toxin (tst) and adhesive proteins (clfA/B, fib, 
fnbA/B) should be investigated to ascertain the repertoire of virulence genes.   
 Other molecular typing techniques that work in tandem with PFGE, such as spa, 
SCCmec and multi locus sequence typing (MLST) must be performed to determine the 
clonal clusters (CC). 
 Further studies involving larger sample sizes from geographically distinct areas in 
South Africa should be conducted to investigate the clonal evolution of MRSA 
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